COMP <GO>
NVCR vs MRK // EV/EBITDA & P/E VALUATION
NovoCure Limited (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: NVCR 1
— MRK 10
■ METRIC PARITY
LAST: $13.15 (+0.31%) • MKT CAP: $1.53B
valuation
—
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVCR VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NVCR | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.50% | 74.80% | -0.30 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.50% | 20.70% | -48.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.96% | 3.42% | -8.38 | MRK | /fcf-yield <GO> |
| Operating Margin | -23.50% | 34.30% | -57.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | -20.80% | 28.10% | -48.90 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 8.30% | 1.30% | +7.00 | NVCR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.54 | 5.19 | -4.65 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 33.8 | 51.7 | -17.90 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.53B | $361.02B | -$359.49B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NVCR REV | MRK REV | NVCR GROSS % | MRK GROSS % | NVCR FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $655.4M | $65.01B | 74.5% | 74.8% | -$75.7M | $12.36B |
| FY 2024 | $605.2M | $64.17B | 77.3% | 76.3% | -$69.2M | $18.10B |
| FY 2023 | $509.3M | $60.12B | — | — | -$73.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVCR // BETA —
MRK // BETA 0.92